151 related articles for article (PubMed ID: 7658750)
21. In vivo anti-tumor activity of synthetic ether lipids is not enhanced by pharmacological modulation of tumor lipid composition.
Diomede L; Damia G; D'Incalci M; Imperatori L; Algeri M; Modest EJ; Salmona M
Int J Cancer; 1994 Nov; 59(4):580-1. PubMed ID: 7960229
[No Abstract] [Full Text] [Related]
22. Lipid rafts, endoplasmic reticulum and mitochondria in the antitumor action of the alkylphospholipid analog edelfosine.
Gajate C; Mollinedo F
Anticancer Agents Med Chem; 2014 May; 14(4):509-27. PubMed ID: 24628241
[TBL] [Abstract][Full Text] [Related]
23. Protein kinase C inhibition by ET-18-OCH3 and related analogs. A target for cancer chemotherapy.
Pauig SB; Daniel LW
Adv Exp Med Biol; 1996; 416():173-80. PubMed ID: 9131145
[No Abstract] [Full Text] [Related]
24. Anticancer mechanisms and clinical application of alkylphospholipids.
van Blitterswijk WJ; Verheij M
Biochim Biophys Acta; 2013 Mar; 1831(3):663-74. PubMed ID: 23137567
[TBL] [Abstract][Full Text] [Related]
25. [The effect of ET-18-OCH3/cholesterol-liposomes on the membrane potentials of isolated endothelial cells].
Mende S; Teuscher E; Lichtnow KH
Pharmazie; 1989 Feb; 44(2):164. PubMed ID: 2748701
[No Abstract] [Full Text] [Related]
26. This month in Investigative Urology. A commentary on suramin demonstrates in vitro toxicity against transitional cell carcinoma cell lines and exposure to alkyllysophospholipids inhibits in vitro invasion of transitional cell carcinoma.
Droller MJ
J Urol; 1994 Nov; 152(5 Pt 1):1356-7. PubMed ID: 7933161
[No Abstract] [Full Text] [Related]
27. Antitumor alkyl-lysophospholipid analog edelfosine induces apoptosis in pancreatic cancer by targeting endoplasmic reticulum.
Gajate C; Matos-da-Silva M; Dakir el-H; Fonteriz RI; Alvarez J; Mollinedo F
Oncogene; 2012 May; 31(21):2627-39. PubMed ID: 22056873
[TBL] [Abstract][Full Text] [Related]
28. Effects of structural modifications of ether lipids on antiproliferative activity against human glioma cell lines.
Berens ME; Bar-Shira E; Rosenblum ML; Piantadosi C; Modest EJ
Anticancer Res; 1993; 13(2):401-5. PubMed ID: 8517654
[TBL] [Abstract][Full Text] [Related]
29. Invasion and metastasis control: implications for increased therapeutic index of antitumor drugs.
Mareel M; Bracke M; Bruyneel E; Van Larebeke N; De Mets M
Cancer Treat Rev; 1990 Sep; 17(2-3):335-8. PubMed ID: 2148711
[No Abstract] [Full Text] [Related]
30. Selective induction of apoptosis in cancer cells by the ether lipid ET-18-OCH3 (Edelfosine): molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-X(L).
Mollinedo F; Fernández-Luna JL; Gajate C; Martín-Martín B; Benito A; Martínez-Dalmau R; Modolell M
Cancer Res; 1997 Apr; 57(7):1320-8. PubMed ID: 9102220
[TBL] [Abstract][Full Text] [Related]
31. Alkyl ether lipids, ion channels and lipid raft reorganization in cancer therapy.
Jaffrès PA; Gajate C; Bouchet AM; Couthon-Gourvès H; Chantôme A; Potier-Cartereau M; Besson P; Bougnoux P; Mollinedo F; Vandier C
Pharmacol Ther; 2016 Sep; 165():114-31. PubMed ID: 27288726
[TBL] [Abstract][Full Text] [Related]
32. The conformational properties of the antineoplastic ether lipid 1-thiohexadecyl-2-O-methyl-S-glycero-3-phosphocholine.
Mavromoustakos T; Theodoropoulou E; Yang DP; Lin SY; Koufaki M; Makriyannis A
Chem Phys Lipids; 1996 Nov; 84(1):21-34. PubMed ID: 8952050
[TBL] [Abstract][Full Text] [Related]
33. Edelfosine, apoptosis, MDR and Na+/H+ exchanger: induction mechanisms and treatment implications.
Harguindey S; Pedraz JL; Cañero RG; Katin M
Apoptosis; 2000 Feb; 5(1):87-9. PubMed ID: 11227496
[No Abstract] [Full Text] [Related]
34. A fluorescent alkyllysophospholipid analog exhibits selective cytotoxicity against the hormone-insensitive prostate cancer cell line PC3.
Samadder P; Byun HS; Bittman R; Arthur G
Anticancer Agents Med Chem; 2014 May; 14(4):528-38. PubMed ID: 24628239
[TBL] [Abstract][Full Text] [Related]
35. Morphological changes of adherent and nonadherent cells by treatment with hexadecylphosphocholine and 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine observed by scanning electron microscopy.
Kaufmann-Kolle P; Fleer EA
Prog Exp Tumor Res; 1992; 34():47-58. PubMed ID: 1438802
[No Abstract] [Full Text] [Related]
36. Hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine: a comparison of hemolytic activity, serum binding and tissue distribution.
Kötting J; Marschner NW; Neumüller W; Unger C; Eibl H
Prog Exp Tumor Res; 1992; 34():131-42. PubMed ID: 1438796
[No Abstract] [Full Text] [Related]
37. Programmed cell death in response to alkyllysophospholipids in endothelial cells.
Araki S; Tsuna I; Kaji K; Hayashi H
J Biochem; 1994 Feb; 115(2):245-7. PubMed ID: 8206873
[TBL] [Abstract][Full Text] [Related]
38. New approaches in cancer pharmacology: drug design and development. Report of a European School of Oncology Task Force.
Eur J Cancer; 1992; 28A(6-7):1190-200. PubMed ID: 1627393
[No Abstract] [Full Text] [Related]
39. An efficient new route to plasmenyl-type lipids: synthesis and cytotoxicity of a plasmenylcholine analogue of the antitumor ether lipid ET-18-OMe.
Shin J; Qualls MM; Boomer JA; Robarge J; Thompson DH
J Am Chem Soc; 2001 Jan; 123(3):508-9. PubMed ID: 11456559
[No Abstract] [Full Text] [Related]
40. Langmuir monolayer study toward combined antileishmanian therapy involving amphotericin B and edelfosine.
Hac-Wydro K; Dynarowicz-Łatka P; Zuk R
J Phys Chem B; 2009 Oct; 113(43):14239-46. PubMed ID: 19845406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
